食管癌RUNX3蛋白的表达特点及意义

Down regulation of RUNX3 expression in esophageal cacinoma and its significance

关键词:  食管癌  RUNX3  蛋白表达  免疫组织化学染色

Key words:  esophageal carcinomar  RUNX3  protein expression  immunohistochemistry

摘要:

[目的]了解RUNX3蛋白在食管癌中的表达及病理学意义。[方法]将手术切除癌旁相对正常食管组织9例、癌前病变38例与食管癌组织83例制成石蜡包埋组织微阵列，用免疫组织化学方法检测RUNX3的表达，并分析其表达与食管癌侵袭及转移的关系。 [结果]癌旁、癌前病变到食管癌组织RUNX3蛋白表达率分别为77.8%、78.9% 与42.2%。食管癌组显著低于癌旁相对正常组、癌前病变组（P<0.05）。食管癌中RUNX3蛋白在淋巴结转移组表达率为22.7%，显著低于无淋巴结转移组的64.1%(P<0.05)，浸润深度T3、4组（31.0%）显著低于T1、2 组68.0%(P<0.05)；III-IV期患者组（32.5%）低于I-II期组（51.2%），但差异无显著性意义(P>0.05)。 [结论]RUNX3蛋白表达下调可能与食管癌的发生发展有关。

Abstract:

[Objectives]To profile the expression characteristics of RUNX3 in esophageal carcinogenesis and explore its pathological significance.[Methods]Nine relative normal esophagus, 38 precancerous lesion and 83 esophageal carcinoma tissues (EC) without preoperative chemo/radiotherapy were selected to manufacture the paraffin embedded tissue array. The expression of RUNX3 was detected by immunohistochemistry, the correlation of RUNX3 expressions to EC invasiveness and metastasis were analyzed. [Results]The rates of RUNX3 expression in normal tissue , precancerous and EC were 77.8%, 78.9% and 42.2%, respectively(P<0.05). There were significant differences between the EC group and noncancerous or precancerous lesion, the rate of EC group was significantly lower than those of normal and precancerous groups(P>0.05). The rate of lymphatic metastasis group 22.7% was significantly lower than that of without 64.1% (P<0.05) as well as the rate in stage T3,4 group(31.0%) was significantly lower than that in stage T1,2 group(68.0%) (P<0.05). The rate in clinical stage III-IV (32.5%) was lower than that in the clinical stage I-II (51.2%), but no significant difference was found(P>0.05). [Conclusion]The characteristics of RUNX3 expression is one of important molecular events throughout esophageal carcinogenesis and dissemination which is closely related to the development of EC. It may be a potencial biomarker in oncological molecular diagnosis and prognosis prediction for EC.